Discure Technologies

Executive Summary

Discure Technologies is an Israeli med-tech company pioneering a minimally invasive, implantable bio-electronic device to treat degenerative disc disease, a leading cause of chronic low back pain. The device restores healthy fluid dynamics in intervertebral discs, aiming to reverse degeneration, reduce pain, and improve spinal function without the need for hospitalization or extensive rehabilitation. Founded in 2020 and currently in Phase 2 clinical development, the company addresses a large unmet need in the orthopedic and spine markets, where current treatments are limited to pain management or invasive surgeries. With strong IP and a novel mechanism of action, Discure has the potential to become a first-in-class disease-modifying therapy for millions of patients worldwide. Discure is executing its pivotal clinical strategy, with focused efforts to demonstrate safety and efficacy in a controlled patient population. The company benefits from a seasoned management team and a supportive regulatory environment in Israel and Europe. As it progresses toward commercialization, near-term catalysts include completion of patient enrollment, release of interim data, and potential regulatory designations. Success in these milestones could significantly de-risk the technology and pave the way for partnerships or further funding. Discure represents a compelling investment opportunity in the high-growth bioelectronic medicine space.

Upcoming Catalysts (preview)

• Q3 2026Completion of Phase 2 patient enrollment80% success
• Q4 2026Interim efficacy/safety data readout70% success
• Q1 2027FDA Breakthrough Device Designation or CE Mark submission65% success